Cessation of Smoke Exposure Improves Pediatric CF Outcomes: Longitudinal Analysis of CF Foundation Patient Registry Data

Overview

Journal J Cyst Fibros

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2021 Jul 20

PMID 34281808

Citations 5

Authors

Gabriela R Oates

Elizabeth Baker

Joseph M Collaco

Steven M Rowe

Sarah B Rutland

Christopher M Fowler

William T Harris

Affiliations

Soon will be listed here.

Abstract

Background: Tobacco smoke exposure is a major risk factor for the health of children and adolescents with CF. In this study, we assess whether cessation of smoke exposure is associated with improved outcomes in this population.

Methods: We used annualized and encounter-based data from the U.S. CF Foundation Patient Registry (2006-2018) on all individuals born 1998-2010. The analytical sample included those who ever reported second-hand smoke exposure (daily or weekly), ever lived with a smoker, or ever reported smoking themselves. We used non-linear mixed models for pulmonary exacerbations and linear mixed models for ppFEV and BMI as a function of ceased exposure.

Results: The sample included 3,633 individuals contributing 19,629 person-years. Cessation of smoke exposure reduced the odds of a pulmonary exacerbation in 12 months by 17% (OR 0.83, p < 0.001) in the first year of cessation, with an additional 6% decrease (OR 0.94, p = 0.003) for each additional year of cessation. Cessation was associated with improvements in ppFEV and BMI: 0.7% ppFEV increase (p < 0.001) in the first year of cessation and 0.4% increase (p = 0.001) for each additional year of cessation; 1% increase in BMI percentile (p < 0.001) in the first year of cessation plus 0.4% increase (p = 0.009) for each additional year. Three years of cessation reduce the predicted probability of a pulmonary exacerbation in 12 months by 8% and improve ppFEV and BMI by 2%.

Conclusion: Eliminating smoke exposure may reduce pulmonary exacerbations and improve respiratory and nutritional outcomes in children and adolescents with CF. Both smoking cessation and exposure prevention should be prioritized in pediatric CF care.

Citing Articles

Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL).

Baker E, Harris W, Guimbellot J, Bliton K, Rowe S, Raju S J Cyst Fibros. 2024; 23(5):959-966.

PMID: 39033068 PMC: 11410542. DOI: 10.1016/j.jcf.2024.07.010.

Social-environmental phenotypes of rapid cystic fibrosis lung disease progression in adolescents and young adults living in the United States.

Palipana A, Vancil A, Gecili E, Rasnick E, Ehrlich D, Pestian T Environ Adv. 2023; 14.

PMID: 38094913 PMC: 10718514. DOI: 10.1016/j.envadv.2023.100449.

Aiming to Improve Equity in Pulmonary Health: Cystic Fibrosis.

Oates G, Schechter M Clin Chest Med. 2023; 44(3):555-573.

PMID: 37517835 PMC: 10458995. DOI: 10.1016/j.ccm.2023.03.011.

Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Oates G, Schechter M Expert Rev Respir Med. 2022; 16(6):637-650.

PMID: 35705523 PMC: 9329222. DOI: 10.1080/17476348.2022.2090928.

Speaking of pandemics.

Schechter M J Cyst Fibros. 2021; 20(4):564-565.

PMID: 34103249 PMC: 8753347. DOI: 10.1016/j.jcf.2021.04.017.

References

Kotz D, West R . Explaining the social gradient in smoking cessation: it's not in the trying, but in the succeeding. Tob Control. 2008; 18(1):43-6. DOI: 10.1136/tc.2008.025981. View

Lewis B, Sultana R, Sharma R, Noel A, Langohr I, Patial S . Early Postnatal Secondhand Smoke Exposure Disrupts Bacterial Clearance and Abolishes Immune Responses in Muco-Obstructive Lung Disease. J Immunol. 2017; 199(3):1170-1183. DOI: 10.4049/jimmunol.1700144. View

Courville C, Raju S, Liu B, Accurso F, Dransfield M, Rowe S . Recovery of Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction after Smoking Cessation. Am J Respir Crit Care Med. 2015; 192(12):1521-4. PMC: 4731718. DOI: 10.1164/rccm.201502-0396LE. View

Oates G, Baker E, Rowe S, Gutierrez H, Schechter M, Morgan W . Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis. J Cyst Fibros. 2020; 19(5):783-790. PMC: 7429279. DOI: 10.1016/j.jcf.2020.02.004. View

West R, McEwen A, Bolling K, Owen L . Smoking cessation and smoking patterns in the general population: a 1-year follow-up. Addiction. 2001; 96(6):891-902. DOI: 10.1046/j.1360-0443.2001.96689110.x. View

Collaco J, Vanscoy L, Bremer L, Mcdougal K, Blackman S, Bowers A . Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA. 2008; 299(4):417-24. PMC: 3139475. DOI: 10.1001/jama.299.4.417. View

Sexton K, Adgate J, Church T, Hecht S, Ramachandran G, Greaves I . Children's exposure to environmental tobacco smoke: using diverse exposure metrics to document ethnic/racial differences. Environ Health Perspect. 2004; 112(3):392-7. PMC: 1241873. DOI: 10.1289/ehp.6473. View

Creamer M, Wang T, Babb S, Cullen K, Day H, Willis G . Tobacco Product Use and Cessation Indicators Among Adults - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(45):1013-1019. PMC: 6855510. DOI: 10.15585/mmwr.mm6845a2. View

Ortega-Garcia J, Lopez-Fernandez M, Llano R, Pastor-Vivero M, Mondejar-Lopez P, Sanchez-Sauco M . Smoking prevention and cessation programme in cystic fibrosis: integrating an environmental health approach. J Cyst Fibros. 2011; 11(1):34-9. PMC: 3260390. DOI: 10.1016/j.jcf.2011.09.005. View

10.

Kotz D, Batra A, Kastaun S . Smoking Cessation Attempts and Common Strategies Employed. Dtsch Arztebl Int. 2020; 117(1-2):7-13. PMC: 7008148. DOI: 10.3238/arztebl.2020.0007. View

11.

Collaco J, Blackman S, McGready J, Naughton K, Cutting G . Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J Pediatr. 2010; 157(5):802-7.e1-3. PMC: 2948620. DOI: 10.1016/j.jpeds.2010.05.018. View

12.

Sanders D, Emerson J, Ren C, Schechter M, Gibson R, Morgan W . Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. Ann Am Thorac Soc. 2015; 12(8):1170-6. PMC: 4566413. DOI: 10.1513/AnnalsATS.201504-198OC. View

13.

Kopp B, Ortega-Garcia J, Sadreameli S, Wellmerling J, Cormet-Boyaka E, Thompson R . The Impact of Secondhand Smoke Exposure on Children with Cystic Fibrosis: A Review. Int J Environ Res Public Health. 2016; 13(10). PMC: 5086742. DOI: 10.3390/ijerph13101003. View

14.

Campbell 3rd P, Parker R, Roberts B, Krishnamani M, Phillips 3rd J . Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion. J Pediatr. 1992; 120(2 Pt 1):261-4. DOI: 10.1016/s0022-3476(05)80438-x. View

15.

Li D, Keogh R, Clancy J, Szczesniak R . Flexible semiparametric joint modeling: an application to estimate individual lung function decline and risk of pulmonary exacerbations in cystic fibrosis. Emerg Themes Epidemiol. 2017; 14:13. PMC: 5699130. DOI: 10.1186/s12982-017-0067-1. View

16.

Prochaska J, Benowitz N . The Past, Present, and Future of Nicotine Addiction Therapy. Annu Rev Med. 2015; 67:467-86. PMC: 5117107. DOI: 10.1146/annurev-med-111314-033712. View

17.

Hassanzad M, Eslampanah S, Modaresi M, Tashayoie-Nejad S, Velayati A . Pulmonary Function and Hospital Admission in Patients with Cystic Fibrosis Based on Household Second-Hand Smoking. Tanaffos. 2018; 17(1):37-41. PMC: 6087526. View

18.

Merianos A, Jandarov R, Choi K, Mahabee-Gittens E . Tobacco smoke exposure disparities persist in U.S. children: NHANES 1999-2014. Prev Med. 2019; 123:138-142. PMC: 6534457. DOI: 10.1016/j.ypmed.2019.03.028. View

19.

Baker E, Harris W, Rowe S, Rutland S, Oates G . Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis. J Cyst Fibros. 2020; 20(4):612-617. PMC: 8018981. DOI: 10.1016/j.jcf.2020.09.011. View

20.

Bhatt J . Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev. 2013; 22(129):205-16. PMC: 9487366. DOI: 10.1183/09059180.00006512. View